← Back to Search

Dietary Supplement

COMP-4 Supplementation for Endothelial Dysfunction

Phase 1 & 2

Recruiting

Led By Sriram V. Eleswarapu, MD PhD

Research Sponsored by University of California, Los Angeles

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 35 subjects in approx. 9 months

Awards & highlights

Study Summary

This trial will test if a clinically available supplement can safely improve blood flow and reduce inflammation in healthy people, which may prevent cardiovascular disease in those prone to it.

Eligible Conditions

Endothelial Dysfunction
Aging

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 35 subjects in approx. 9 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~35 subjects in approx. 9 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 35 subjects in approx. 9 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Interleukin-8

To study the effect of short-term use of daily COMP-4 on flow mediated dilation (FMD) of the brachial artery in young, generally healthy men and women.

Secondary outcome measures

To further evaluate for side effects of COMP-4 use

Trial Design

1Treatment groups

Experimental Treatment

Group I: Experimental GroupExperimental Treatment1 Intervention

All subjects recruited in this study will be in the experimental group receiving the oral supplement, COMP-4, twice daily for 14 days.

Do I qualify?Apply below to find out

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

University of California, Los AngelesLead Sponsor

1,528 Previous Clinical Trials

10,276,816 Total Patients Enrolled

5 Trials studying Endothelial Dysfunction

329 Patients Enrolled for Endothelial Dysfunction

Sriram V. Eleswarapu, MD PhDPrincipal InvestigatorUniversity of California, Los Angeles

Media Library

COMP-4 (Dietary Supplement) Clinical Trial Eligibility Overview. Trial Name: NCT05595915 — Phase 1 & 2

Endothelial Dysfunction Research Study Groups: Experimental Group

Endothelial Dysfunction Clinical Trial 2023: COMP-4 Highlights & Side Effects. Trial Name: NCT05595915 — Phase 1 & 2

COMP-4 (Dietary Supplement) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05595915 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are middle-aged adults welcome in this trial?

"The age limit to participate in this study is 39 years old. All applicants must also be above the age of majority."

Answered by AI

Would I be able to help out with this research project?

"To be applicable for this study, potential participants must be aged 18-39 and show visible signs of aging. So far, 35 individuals have been recruited."

Answered by AI

Are people with the condition under study currently being accepted into this research project?

"As can be seen on clinicaltrials.gov, this particular trial is not looking for new candidates at the moment. The study was first posted on November 15th, 2022 and was last updated October 24th, 2022. Although this research project isn't currently active, there are 291 other trials that are searching for participants."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

COMP-4 Supplementation and Brachial Artery FMD

Sriram Eleswarapu 2023. "COMP-4 Supplementation and Brachial Artery FMD". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05595915.